【NEWS】Cyto-Facto Selected for Regenerative CDMO Subsidy
2025/07/16
July 16, 2025
Cyto-Facto Inc.
Cyto-Facto Selected for METI’s “Subsidy Program for Regenerative, Cell, and Gene Therapy Manufacturing Facilities (Regenerative CDMO Subsidy)”
Cyto-Facto Inc. (Headquarters: Kobe, Japan; President & CEO: [Name]) is pleased to announce that the company has been selected by the Ministry of Economy, Trade and Industry (METI) for the “Subsidy Program for Regenerative, Cell, and Gene Therapy Manufacturing Facilities (Regenerative CDMO Subsidy)” as of July 15, 2025.
Through this program, Cyto-Facto will expand its manufacturing facilities specialized in cell and gene therapy products such as CAR-T, demonstrate labor cost reduction through automation, and implement a cloud-based manufacturing management system to enhance operational efficiency, optimize production processes, and reduce costs. In addition, the company will strengthen collaboration with global partners to establish a Quality Management System (QMS) aligned with international standards.
About the “Regenerative CDMO Subsidy”
This subsidy program is designed to strengthen the manufacturing infrastructure for regenerative, cell, and gene therapies by supporting CDMO investments in facilities, adoption of next-generation manufacturing technologies (such as automation and quality management systems), and workforce development. The program aims to industrialize Japan’s world-class R&D outcomes by promoting efficient, stable manufacturing processes and fostering the global expansion of the regenerative medicine sector. For details, please visit the official website: http://cdmo-hojo.jp.
About Cyto-Facto Inc.
Cyto-Facto Inc. is a Contract Development and Manufacturing Organization (CDMO) specialized in regenerative medicine and advanced therapy products. Based in Kobe, Japan, the company operates multiple PICS GMP- and CGTP-compliant facilities and provides end-to-end services from early development to commercial manufacturing. Cyto-Facto supports a wide range of modalities, including CAR-T, MSC, and iPSC-derived products, and is committed to enabling the global advancement of cell and gene therapies.
Contact Information
Cyto-Facto Inc.
Business Strategy Department
E-mail: info@cytofacto.com
Cyto-Facto Inc.
Cyto-Facto Selected for METI’s “Subsidy Program for Regenerative, Cell, and Gene Therapy Manufacturing Facilities (Regenerative CDMO Subsidy)”
Cyto-Facto Inc. (Headquarters: Kobe, Japan; President & CEO: [Name]) is pleased to announce that the company has been selected by the Ministry of Economy, Trade and Industry (METI) for the “Subsidy Program for Regenerative, Cell, and Gene Therapy Manufacturing Facilities (Regenerative CDMO Subsidy)” as of July 15, 2025.
Through this program, Cyto-Facto will expand its manufacturing facilities specialized in cell and gene therapy products such as CAR-T, demonstrate labor cost reduction through automation, and implement a cloud-based manufacturing management system to enhance operational efficiency, optimize production processes, and reduce costs. In addition, the company will strengthen collaboration with global partners to establish a Quality Management System (QMS) aligned with international standards.
About the “Regenerative CDMO Subsidy”
This subsidy program is designed to strengthen the manufacturing infrastructure for regenerative, cell, and gene therapies by supporting CDMO investments in facilities, adoption of next-generation manufacturing technologies (such as automation and quality management systems), and workforce development. The program aims to industrialize Japan’s world-class R&D outcomes by promoting efficient, stable manufacturing processes and fostering the global expansion of the regenerative medicine sector. For details, please visit the official website: http://cdmo-hojo.jp.
About Cyto-Facto Inc.
Cyto-Facto Inc. is a Contract Development and Manufacturing Organization (CDMO) specialized in regenerative medicine and advanced therapy products. Based in Kobe, Japan, the company operates multiple PICS GMP- and CGTP-compliant facilities and provides end-to-end services from early development to commercial manufacturing. Cyto-Facto supports a wide range of modalities, including CAR-T, MSC, and iPSC-derived products, and is committed to enabling the global advancement of cell and gene therapies.
Contact Information
Cyto-Facto Inc.
Business Strategy Department
E-mail: info@cytofacto.com
プレスリリース_2507再生CDMO補助金採択_en(227.91 KB)
- To view PDF files, you need Adobe Reader. Download it for free here.
- When PDF file is large, it might take some time to load.